TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2248921

Group type: EXPERIMENTAL
Intervention: DexSol containing recombinant hEGF and human insulin
Number of subjects: 105

Group type: COMPARATOR
Intervention: DexSol (CSM with 1% dextran)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 6113234

Group type: EXPERIMENTAL
Intervention: Prazeapm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (Prazeapm, Diazepam, Lorazepam, Placebo)
Number of subjects: 0
Study: 30622223

Group type: EXPERIMENTAL
Intervention: Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone
Number of subjects: 93

Group type: COMPARATOR
Intervention: Group L: 20 ml 0.25% levobupivacaine + 1 ml normal saline (NS)
Number of subjects: 93
Study: 28640161

Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% (6.5 mg) prasterone
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study: 25489056

Group type: EXPERIMENTAL
Intervention: Canned beverages
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glass bottled beverages
Number of subjects: 60
Study: 22381828

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard anesthetic management)
Number of subjects: 100
Study: 19679575

Group type: EXPERIMENTAL
Intervention: Custom-made, semirigid running shoe orthoses
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (regular training activity without treatment)
Number of subjects: 51
Study: 19853886

Group type: EXPERIMENTAL
Intervention: Home remediation
Number of subjects: 117
Study: 16754934

Group type: EXPERIMENTAL
Intervention: Epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by involved-field radiotherapy (IF-RT) in favorable patients
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: MOPP/ABV hybrid followed by IF-RT in unfavorable patients
Number of subjects: 722

Group type: COMPARATOR
Intervention: Epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by IF-RT in unfavorable patients
Number of subjects: 722

Group type: COMPARATOR
Intervention: Subtotal nodal irradiation (STNI) in favorable patients
Number of subjects: 722
Study: 16133950

Group type: EXPERIMENTAL
Intervention: Late evidence disclosure
Number of subjects: 116

Group type: COMPARATOR
Intervention: Early evidence disclosure
Number of subjects: 116
Study: 12353677

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 1 week
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 2 weeks
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream for 4 weeks
Number of subjects: 177

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 177
Study: 10407503

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (150 mg ascorbic acid, 67 mg alpha-tocopherol, 9 mg beta-carotene)
Number of subjects: 132

Group type: COMPARATOR
Intervention: B group vitamins (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: B group vitamins with antioxidant vitamins
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 7554453

Group type: EXPERIMENTAL
Intervention: IMREG-1 plus antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antigen alone (control)
Number of subjects: 0
Study: 2210893

Group type: EXPERIMENTAL
Intervention: Gallium-67 imaging
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 44
Study: 6113858

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine suspension
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 180 mg terfenadine suspension
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 60 mg of 14C terfenadine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Urinary excretion of 14C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fecal recovery of 14C
Number of subjects: 14
Study: 30892616

Group type: EXPERIMENTAL
Intervention: Automated text-messaging support (SmokefreeTXT) plus personalized texts from a peer mentor
Number of subjects: 200

Group type: COMPARATOR
Intervention: Automated text-messaging support (SmokefreeTXT)
Number of subjects: 200
Study: 31079480

Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no life review)
Number of subjects: 46
Study: 28849773

Group type: EXPERIMENTAL
Intervention: Double dose (20 µg) hepatitis B vaccine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard dose (10 µg) hepatitis B vaccine
Number of subjects: 55
Study: 25670366

Group type: EXPERIMENTAL
Intervention: Anacetrapib (150 and 300 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anacetrapib + Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin alone vs placebo
Number of subjects: 0
Study: 24386975

Group type: EXPERIMENTAL
Intervention: Feedback to therapist (FbT)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Feedback to therapist and patient (FbTP)
Number of subjects: 475

Group type: COMPARATOR
Intervention: No feedback (NFb)
Number of subjects: 475
Study: 22711385

Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral and herbal supplement (Swisse Men's Ultivite®)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 19031460

Group type: EXPERIMENTAL
Intervention: Quadruple ART (n = 43)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Triple ART (n = 14)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dual ART (n = 15)
Number of subjects: 72
Study: 17376293

Group type: EXPERIMENTAL
Intervention: nateglinide (120 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: acarbose (50 mg)
Number of subjects: 16
Study: 15199325

Group type: EXPERIMENTAL
Intervention: Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTI) from current therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Number of subjects: 0
Study: 11772696

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9640894

Group type: EXPERIMENTAL
Intervention: Safety educational videotape
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Animated cartoon with incidental safety components
Number of subjects: 60

Group type: COMPARATOR
Intervention: Edited cartoon program (omitting safety behavior scenes)
Number of subjects: 60
Study: 8078734

Group type: EXPERIMENTAL
Intervention: Open label IVIG
Number of subjects: 148
Study: 2673590

Group type: EXPERIMENTAL
Intervention: Tuberculin plus M. leprae soluble antigens
Number of subjects: 213

Group type: COMPARATOR
Intervention: Tuberculin alone
Number of subjects: 213
Study: 1190686

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 10 mg/kg intravenously at 8-hour intervals for three doses
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 45
Study: 30216527

Group type: EXPERIMENTAL
Intervention: High nickel-releasing metal discs for 10, 30 and 60 minutes on 3 occasions over a period of 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High nickel-releasing metal discs for repetitive exposures of up to 30 minutes on 3 occasions over a period of 2 weeks
Number of subjects: 45
Study: 27515930

Group type: EXPERIMENTAL
Intervention: Village-wide health education program and availability of salt substitute at village shops
Number of subjects: 1903

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1903
Study: 25267131

Group type: EXPERIMENTAL
Intervention: Family-centered care program (routine hospital services plus a family-centered care program consisting of need assessment, educating families based on patients' needs, follow-ups by short phone interviews, and referral service)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine hospital services (control group)
Number of subjects: 60
Study: 22334056

Group type: EXPERIMENTAL
Intervention: Aerobic training (50 minutes, four times weekly for 24 weeks)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (health lectures twice a month)
Number of subjects: 176
Study: 20639391

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hypertension
Number of subjects: 43
Study: 18549492

Group type: EXPERIMENTAL
Intervention: Stepped care interventions (three step treatment approach: step 1 - behavioural change counselling, step 2 - three sessions of motivational enhancement therapy, step 3 - referral to specialist services)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 0
Study: 16156456

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12610040

Group type: EXPERIMENTAL
Intervention: Insulin glargine prebedtime plus lispro preprandially (LIS/GLAR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: NPH insulin prebedtime plus regular human insulin preprandially (R/NPH)
Number of subjects: 28
Study: 10369072

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy
Number of subjects: 0
Study: 7577201

Group type: EXPERIMENTAL
Intervention: Less extensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 1882110

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Half-lying position
Number of subjects: 7
Study: 7032533

Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 30
Study: 31932201

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement 2000 IU per day for 2 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 149
Study: 29251686

Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 26988095

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs on inhalation techniques (one session with a monitor)
Number of subjects: 267
Study: 25038522

Group type: EXPERIMENTAL
Intervention: CPAP+PAV
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 0
Study: 22454251

Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10 mg BID)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Olanzapine (10 or 20 mg QD)
Number of subjects: 440
Study: 20446847

Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sTNFR-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sCD27
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sCD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of plasma IL-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTNFR-1, sCD27, and sCD40L
Number of subjects: 0
Study: 18021264

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 1 g, 1 h pre-operatively and 2 g for 2 days post-operatively (Antibiotics group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No antibiotics (Non-antibiotics group)
Number of subjects: 80
Study: 15901755

Group type: EXPERIMENTAL
Intervention: SFR (known target location with random head direction)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SFP (known target location with known head direction)
Number of subjects: 6

Group type: COMPARATOR
Intervention: HF trials
Number of subjects: 6

Group type: COMPARATOR
Intervention: SF trials
Number of subjects: 6
Study: 15460663

Group type: EXPERIMENTAL
Intervention: Alcohol intake at 2100 hrs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study: 10638381

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rowers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonathletes
Number of subjects: 20
Study: 9197875

Group type: EXPERIMENTAL
Intervention: Continuous 17 beta‐oestradiol orally (2 mg daily)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Continuous 17 beta‐oestradiol transdermally (50 micrograms daily)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 140
Study: 1527230

Group type: EXPERIMENTAL
Intervention: Methylphenidate or dextroamphetamine in individualized doses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Methylphenidate or dextroamphetamine
Number of subjects: 7
Study: 3549870

Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study: 31036709

Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (various brands)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Unicondylar constructs
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (in men aged 55-75 years)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (in women aged 55-75 years)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Contemporary benchmark construct
Number of subjects: 449
Study: 29102524

Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: SPMC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: PEGA
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control (4L of PEG)
Number of subjects: 612
Study: 26861923

Group type: EXPERIMENTAL
Intervention: High in monounsaturated fat (extra-virgin olive oil)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low fat
Number of subjects: 13

Group type: COMPARATOR
Intervention: High in saturated fat (butter)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-glycemic index meals
Number of subjects: 13
Study: 24944054

Group type: EXPERIMENTAL
Intervention: Whole Grains (WG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refined Grains (RG)
Number of subjects: 50
Study: 23611825

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU orally every 3 months for 4 doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 52
Study: 19926166

Group type: EXPERIMENTAL
Intervention: Routine antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antibiotics unless clinically indicated)
Number of subjects: 0
Study: 18833105

Group type: EXPERIMENTAL
Intervention: Rileptid (generic risperidone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rispolept (original risperidone)
Number of subjects: 0
Study: 16616748

Group type: EXPERIMENTAL
Intervention: Luteal-phase acupuncture
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 225
Study: 14652885

Group type: EXPERIMENTAL
Intervention: 2% prilocaine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 183
Study: 11095136

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 70
Study: 8621005

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Carbohydrates (CHOs)
Number of subjects: 17
Study: 1582188

Group type: EXPERIMENTAL
Intervention: Oxprenolol (non-selective beta-blocker with moderate intrinsic sympathomimetic activity), given by the Oros delivery system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-selective blocker without ISA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30909333

Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 212

Group type: COMPARATOR
Intervention: HP plus TAZ
Number of subjects: 212
Study: 28525401

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 72

Group type: COMPARATOR
Intervention: Airtraq
Number of subjects: 72
Study: 25924860

Group type: EXPERIMENTAL
Intervention: Interdisciplinary team-based (ITB) learning
Number of subjects: 29

Group type: COMPARATOR
Intervention: Individual discipline-based (DB) learning
Number of subjects: 29
Study: 23536963

Group type: EXPERIMENTAL
Intervention: Inhalation of black pepper essential oil for 2 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhalation of angelica essential oil for 2 minutes
Number of subjects: 20
Study: 21300083

Group type: EXPERIMENTAL
Intervention: Workplace POWER program (n=65)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-list control group (n=45)
Number of subjects: 110
Study: 19583067

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 82
Study: 17456491

Group type: EXPERIMENTAL
Intervention: HES 130/0.42
Number of subjects: 50

Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 50
Study: 15161771

Group type: EXPERIMENTAL
Intervention: Pioglitazone (P+) 45 mg for 21 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P-)
Number of subjects: 9
Study: 12101864

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg or 600 mg) and Misoprostol (400 micrograms)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg or 600 mg) and Misoprostol (600 micrograms)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg and Misoprostol (400 micrograms)
Number of subjects: 80
Study: 9867054

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis and randomization concerns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical benefits of steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risks of intervention
Number of subjects: 0
Study: 8079827

Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 2536867

Group type: EXPERIMENTAL
Intervention: Regimen A: eight courses of cyclophosphamide, doxorubicin, and vincristine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Regimen B: two courses of three sequential drug combinations (1) cyclophosphamide, lomustine, and methotrexate; (2) cyclophosphamide, doxorubicin, and vincristine; (3) ifosfamid and etoposide
Number of subjects: 112
Study: 4465285

Group type: EXPERIMENTAL
Intervention: Heterozygotes identified in families of Libyan origin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Randomly screened healthy school children of Libyan origin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Genetically determined cystine urolithiasis frequency
Number of subjects: 24
Study: 30332904

Group type: EXPERIMENTAL
Intervention: Simulation + mastery learning
Number of subjects: 264

Group type: COMPARATOR
Intervention: Simulation without mastery learning (Control)
Number of subjects: 264
Study: 28839341

Group type: EXPERIMENTAL
Intervention: Valbenazine (NBI-98854)
Number of subjects: 430
Study: 25732417

Group type: EXPERIMENTAL
Intervention: UDCA + Bezafibrate (BF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: UDCA monotherapy
Number of subjects: 27
Study: 24308450

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15212

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 15212

Group type: EXPERIMENTAL
Intervention: Ticagrelor (excluding patients who died)
Number of subjects: 15212

Group type: COMPARATOR
Intervention: Clopidogrel (excluding patients who died)
Number of subjects: 15212
Study: 21355914

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 82
Study: 19067726

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17224756

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Applanation resonance tonometry (ARTBiom)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Applanation resonance tonometry (ARTHand)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Measurement order (first vs last method)
Number of subjects: 153
Study: 15142013

Group type: EXPERIMENTAL
Intervention: Resistance training routine (3 sets of 8‐10 repetitions at 75% of 1 repetition maximum) of 8 large muscle mass exercises using resistance machines
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (sat quietly in the training facility)
Number of subjects: 16
Study: 11903412

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (IC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual glycaemic control (UC)
Number of subjects: 43
Study: 9388412

Group type: EXPERIMENTAL
Intervention: Brassiodol (iodised rapeseed oil) at a dose of 2 mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipiodol (poppyseed-based iodised oil)
Number of subjects: 0
Study: 7532743

Group type: EXPERIMENTAL
Intervention: Diabetic patients with elevated S/P ratio
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Diabetic patients with microalbuminuria
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Diabetic patients with long duration of disease
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 718
Study: 3279725

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. with moderate dietary salt reduction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. with hydrochlorothiazide 25 mg daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 27
Study: 31208916

Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening exercises
Number of subjects: 105

Group type: COMPARATOR
Intervention: General functional exercises
Number of subjects: 105